Ocugen (OCGN) Total Non-Current Liabilities (2014 - 2026)
Ocugen's (OCGN) quarterly Total Non-Current Liabilities came in at $30.4 million in Q1 2026, down 4.01% YoY from $31.7 million in Q1 2025, and down 6.88% on a QoQ basis from $32.6 million in Q4 2025.
Ocugen (OCGN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Total Non-Current Liabilities data on file, last reported at $30.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 4.01% year-over-year to $30.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.4 million (down 4.01% YoY) and the FY2025 annual result came in at $32.6 million, up 4.54% from the prior year.
- Total Non-Current Liabilities eased to $30.4 million in Q1 2026, from $32.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $33.7 million in Q3 2025 to a low of $2.9 million in Q1 2022.
- A 5-year average of $14.8 million and a median of $6.0 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities dropped 14.48% — and 2025, when it jumped 507.9%.
- Tracing OCGN's Total Non-Current Liabilities over 5 years: stood at $6.1 million in 2022, then increased by 12.65% to $6.9 million in 2023, then surged by 352.89% to $31.2 million in 2024, then rose by 4.54% to $32.6 million in 2025, then retreated by 6.88% to $30.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $30.4 million (Q1 2026), $32.6 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 7.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.68 Mn |
| Mar 31, 2026 | 30.39 Mn |
| Dec 31, 2025 | 32.64 Mn |
| Sep 30, 2025 | 33.70 Mn |
| Jun 30, 2025 | 32.55 Mn |
| Mar 31, 2025 | 31.66 Mn |
| Dec 31, 2024 | 31.22 Mn |
| Sep 30, 2024 | 5.54 Mn |
| Jun 30, 2024 | 5.64 Mn |
| Mar 31, 2024 | 5.48 Mn |
| Dec 31, 2023 | 6.89 Mn |
| Sep 30, 2023 | 5.16 Mn |
| Jun 30, 2023 | 5.24 Mn |
| Mar 31, 2023 | 4.82 Mn |
| Dec 31, 2022 | 6.12 Mn |
| Sep 30, 2022 | 6.03 Mn |
| Jun 30, 2022 | 5.64 Mn |
| Mar 31, 2022 | 2.91 Mn |
| Dec 31, 2021 | 2.94 Mn |
| Sep 30, 2021 | 2.97 Mn |